Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy

Journal of Infectious Diseases

Volumn 186, Issue 10, 2002, Pages 1403-1411

  Kulkosky, Joseph ^a   Nunnari, Giuseppe ^a   Otero, Miguel ^a   Calarota, Sandra ^a   Dornadula, Geetha ^a   Zhang, Hui ^a   Malin, Anne ^a   Sullivan, Julie ^a   Xu, Yan ^a   DeSimone, Joseph ^a   Babinchak, Timothy ^a   Stern, John ^b   Cavert, Winston ^c   Haase, Ashley ^c   Pomerantz, Roger J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b PENNSYLVANIA HOSPITAL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; HYDROXYUREA; INTERLEUKIN 2; OKT 3; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD TOXICITY; CASE REPORT; ERADICATION THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MORBIDITY; MORTALITY; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; SIDE EFFECT; TOXICITY; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY; MALE;

EID: 0037111060     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/344357     Document Type: Article

References (44)

1. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
3. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-5.
4. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active anti-retroviral therapy. Science 1997;278:1295-300.
5. Chun T-W, Stuyver L, Mizell SB, et al. Presence of an inducible HIV- 1 latent reservoir during highly active anti-retroviral therapy. Proc Natl Acad Sci USA 1997;94:13193-7.
6. Zhang H, Dornadula G, Beumont M, et al. HIV-1 in the semen of men receiving highly active anti-retroviral therapy. N Engl J Med 1998;339:1803-9.
7. Pomerantz RJ. Residual HIV-1 infection during antiretroviral therapy: The challenge of viral persistence. AIDS 2001;15:1201-11.
8. Sanchez G, Xu X, Chermann JC, Hirsch I. Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. J Virol 1997;71:2233-40.
9. Sonza S, Mutimer HP, Oelrichs R, et al. Monocytes harbour replicationcompetent, non-latent HIV in patients on highly active antiretroviral therapy. AIDS 2001;15:17-22.
10. + monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol 2002;76:707-16.
11. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340:1605-13.
12. Martinez MA, Cababa M, Ibanez A, Clotet B, Arno A, Ruiz L. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged depression of plasma viremia. Virology 1999;256:180-7.
13. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999;340:1614-22.
14. Sharkey ME, Teo L, Greenough T, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy. Nat Med 2000;6:76-81.
15. Hauber I, Harrer T, Low P, et al. Determination of HIV-1 circular DNA as a surrogate marker for residual virus replication in patients with undetectable virus loads. AIDS 2000;14:2619-21.
16. Patterson BK, McCalistera S, Schutz M, et al. Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART. AIDS 2001;15:1635-41.
17. Zhang J, Crumpacker CS. Human immunodeficiency virus type 1 RNA in peripheral blood mononuclear cells of patients receiving prolonged highly active antiretroviral therapy. J Infect Dis 2001;184:1341-4.
18. Dornadula G, Nunnari G, Vanella M, et al. Human immunodeficiency virus type 1-infected persons with residual disease and viral reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups. J Infect Dis 2001;183:1682-7.
19. Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ, Siliciano RF. Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol 2002;76:4138-44.
20. Butler SL, Johnson EP, Bushman FD. Human immunodeficiency virus cDNA metabolism: Notable stability of two-long terminal repeat circles, J Virol 2002;76:3739-47.
21. Dornadula G, Zhang H, Van Uitert B, et al. Residual HIV-1 RNA in the blood plasma of patients on suppressive highly active anti-retroviral therapy (HAART). JAMA 1999;282:1627-32.
22. Yerly S, Perneger TV, Vora S, et al. Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection. AIDS 2000;14:2805-12.
23. + T-cells in HIV-1-infected patients receiving highly active antiretroviral therapy. Nat Med 1999;5:651-5
24. Davey RT Jr, Bhat N, Yoder C, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999;96:15109-14.
25. Prins JM, Jurriaans S, van Praaga RME, et al. Immunoactivation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 1999;13:2405-10.
26. Fraser C, Ferguson NM, Ghani AC, et al. Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs. AIDS 2000;14:659-69.
27. Pomerantz RJ, Zhang H. Residual HIV-1 persistence during suppressive HAART. In: Remington J, Swartz M, eds. Current Clinical Topics in Infectious Diseases. Malden, MA: Blackwell Science, 2001:1-30.
28. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus type 1 replication. Science 1994;266:801-4.
29. Sosman JA, Weiss GR, Margolin KA, et al. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: Clinical and immunologic effects. J Clin Oncol 1993;11:1496-505.
30. Sosman JA, Kefer C, Fisher RI, Jacobs CD, Pumfery P, Ellis TM. A phase IA/IB trial of anti-CD3 murine monoclonal antibody plus low-dose continuous-infusion interleukin-2 in advanced cancer patients. J Immunother Emphasis Tumor Immunol 1995;17:171-80.
31. Havli DV, Gilbert PB, Bennett K, et al. Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. AIDS 2001;15:1379-88.
32. Urba WJ, Ewel C, Kopp W, et al. Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: A phase IA/B study. Cancer Res 1992;52:2394-401.
33. Richards J, Auger J, Peace D, et al. Phase I evaluation of humanized OKT3: Toxicity and immunomodulatory effects of hOKT3g4. Cancer Res 1999;59:2096-01.
34. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following P-2 OKT3 administration: Systemic cytokine release and modulation by corticosteroids. Transplantation 1990;49:697-702.
35. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997;276:960-4.
36. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-6.
37. Lafeuillade A, Poggi C, Chadapaud S, et al. Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission. J Acquir Immune Defic Syndr 2001;26:44-55.
38. Garcia F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999;13:F79-86.
39. Zhang L, Chung C, Hu BS, et al. Genetic characterization of rebounding of HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest 2000;106:839-45.
40. Chun TW, Davey RT, Ostrowski M, et al. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active antiretroviral therapy. Nat Med 2000;6:757-61.
41. Imamichi H, Crandel KA, Nataranjan V, et al. Human immunodeficiency virus type I quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J Infect Dis 2001;183:36-50.
42. Winston JA, Bruggeman LA, Ross MD, et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001;344:1979-84.
43. Brooks DG, Zack JA. Effect of latent HIV infection on cell surface phenotype. J Virol 2002;76:1673-81.
44. Nunnari G, Otero M, Dornadula G, et al. Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: Latency without ongoing cellular infections. AIDS 2002;16:39-45.